Antithrombin Iii Patents (Class 530/393)
-
Patent number: 11059857Abstract: A chromatographic method for collecting blood coagulation factor VII (Factor VII) and/or activated blood coagulation factor VII (activated Factor VII) from plasma-derived fractions with high yield is provided. In accordance with the method of the present invention, Factor VII and/or activated Factor VII of interest can be collected with a recovery rate of as high as 90% or more by letting Factor VII and/or activated Factor VII which fails to be adsorbed to a first anion exchange resin and remains in a non-adsorption fraction be adsorbed in a second anion exchange resin.Type: GrantFiled: December 20, 2017Date of Patent: July 13, 2021Assignee: KM BIOLOGICS CO., LTD.Inventors: Kentaro Ebisu, Takashi Kai, Nozomi Matsuo
-
Publication number: 20150147345Abstract: This document relates to conjugates of a biologically active molecule or a derivative thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.Type: ApplicationFiled: June 12, 2013Publication date: May 28, 2015Inventor: Marek Kwiatkowski
-
Patent number: 8822654Abstract: The present invention relates to the use of a composition including of at least a mutated antithrombin having an anticoagulant activity substantially reduced with respect to the anticoagulant activity of the non mutated antithrombin, or having no anticoagulant activity, for the preparation of a drug intended for the prevention or the treatment of pathologies associated with cellular injury, such as infection, inflammation or hypoxic injury.Type: GrantFiled: January 15, 2010Date of Patent: September 2, 2014Assignees: Universite Paris—Sud XI, Assistance Publique-Hopitaux de Paris, Universite Paris DescartesInventors: Delphine Borgel, Véronique Ferger, Elsa Bianchini, Nicolas Lerolle, Jean-Luc René Diehl
-
Publication number: 20140242182Abstract: In one aspect, the disclosure provides formulations that stabilize proteins, wherein the formulations comprise a buffer. In some embodiments, the buffer comprises potassium mono-hydrogen-phosphate and potassium di-hydrogen-phosphate, or the buffer comprises sodium mono-hydrogen-phosphate and sodium di-hydrogen-phosphate. In some embodiments, the protein is a therapeutic protein. In some embodiments, the therapeutic protein is antithrombin.Type: ApplicationFiled: July 6, 2012Publication date: August 28, 2014Applicant: rEVO Biologics, IncInventors: Sean A. Evans, Greg J. Allard, Nicholas C. Masiello
-
Publication number: 20140148585Abstract: The present invention relates to protein purification. More particularly, a method for directly recovering an objective protein from a protein composition and purifying a protein with a desired quality in a rapid and efficient manner is provided. Further, a rapid purification method capable of efficiently removing impurities included in the protein composition is provided. Therefore, compared to the conventional purification methods, quality and yield of the protein can be remarkably improved.Type: ApplicationFiled: June 28, 2012Publication date: May 29, 2014Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Tsutomu Sugihara, Tomoko Isoda, Yuya Taniguchi, Hidetaka Nomura, Toshiyuki Suzawa
-
Patent number: 8648177Abstract: Method for lyophilization is provided, in particular methods for lyophilization of formulations comprising AT III. Also provided are compositions prepared by therefrom. Also provided are kits comprising the compositions and/or lyophilized products.Type: GrantFiled: November 23, 2010Date of Patent: February 11, 2014Assignee: Grifols Therapeutics Inc.Inventors: Jianxin Guo, Anthony Klos, Deborah Barnette
-
Patent number: 8618266Abstract: The present invention relates to hydroxyalkylstarch (HAS)-polypeptide-conjugate (HAS-polypeptide) comprising one or more HAS molecules, wherein each HAS is conjugated to the polypeptide via a carbohydrate moiety or a thioether as well as to methods for the production thereof. In a preferred embodiment, the polypeptide is erythropoietin (EPO).Type: GrantFiled: March 11, 2005Date of Patent: December 31, 2013Assignee: Fresenius Kabi Deutschland GmbHInventors: Harald S. Conradt, Eckart Grabenhorst, Manfred Nimtz, Norbert Zander, Ronald Frank, Wolfram Eichner
-
Patent number: 8216788Abstract: The present disclosure relates to methods and compositions for the detection of infectious proteins or prions in samples, including the diagnosis of prion related diseases. One embodiment is an ultrasensitive method for detecting PrP-res (PrPSc) that allows the use of recombinant PrP-sen (rPrP-sen) as a substrate for seeded polymerization. A sample is mixed with purified rPrP-sen to make a reaction mix which is incubated to permit aggregation of the rPrP-sen with the PrP-res that may be present in the sample. Any aggregates are intermittently disaggregated by agitation (for example by sonication) and the reaction allowed to proceed to amplify target substrate. Any rPrP-res(Sc) in the reaction mix is detected to indicate the presence of PrP-res in the original sample. This assay, which is called rPrP-PMCA, is surprisingly much faster than existing PMCA methods, yet it still retains sufficient sensitivity to detect extremely low levels of PrP-res.Type: GrantFiled: July 21, 2008Date of Patent: July 10, 2012Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Byron W. Caughey, Ryuichiro Atarashi, Roger A. Moore
-
Publication number: 20120135931Abstract: The present invention relates to a method of modifying serine protease inhibitors in order to acquire or enhance any one of a variety of desired properties, including extent of inhibition, maintenance of inhibition following cleavage of the serine protease inhibitor by the target serine protease, speed of binding to the serine protease, neutralisation, and binding affinity. The present invention also relates to the products of such modifications and the uses of such products, in particular, their use in therapy.Type: ApplicationFiled: May 5, 2010Publication date: May 31, 2012Applicant: NATURAL ENVIRONMENT RESEARCH COUNCILInventors: R. Manjunatha Kini, Cho Yeow Koh, Kunchithapadam Swaminathan, Kumar Sundramurthy
-
Publication number: 20120088715Abstract: The present invention relates to the use of a composition including of at least a mutated antithrombin having an anticoagulant activity substantially reduced with respect to the anticoagulant activity of the non mutated antithrombin, or having no anticoagulant activity, for the preparation of a drug intended for the prevention or the treatment of pathologies associated with cellular injury, such as infection, inflammation or hypoxic injury.Type: ApplicationFiled: January 15, 2010Publication date: April 12, 2012Applicants: UNIVERSITE PARIS-SUD XI, UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE-HOPITAUX DE PARISInventors: Delphine Borgel born Botbol, Veronique Ferger born Picard, Elsa Bianchini, Nicolas Lerolle, Rene Jean-Luc Diehl
-
Patent number: 8084580Abstract: The invention discloses a purified albumin solution of human origin with low prekallicrein activator (PKA) activity and stability over time characterized in that it has an antithrombin content equal to or greater than 0.03 mg/g of albumin, and a process for production thereof by the partial extraction of the antithrombin during fractionation of the human plasma.Type: GrantFiled: March 21, 2007Date of Patent: December 27, 2011Assignee: Grifols, S.A.Inventors: Juan Ignacio Jorquera Nieto, Nuria Hosta Mateu, Olga Santaeularia Lozano
-
Patent number: 8076462Abstract: The provision of an antithrombin composition having a desired ?-form content rate or ?-form content rate is required. The invention provides a process for producing an antithrombin composition having a desired ?-form content rate or ?-form content rate which is prepared by contacting an antithrombin-containing aqueous solution with a Cellufine Sulfate chromatography carrier.Type: GrantFiled: April 2, 2008Date of Patent: December 13, 2011Assignee: Kyowa Hakko Kirin Co., LtdInventors: Tsutomu Sugihara, Setsuko Onodera, Tomonari Urakubo, Toshiyuki Suzawa
-
Publication number: 20110195478Abstract: The present invention discloses a bladder cancer biomarker and a test method using the same. The biomarker contains at least one of the mentioned 69 compounds, such as apolipoprotein A1 (APOA1), apolipoprotein A2 (APOA2), peroxiredoxin 2 (PRDX2), heparin cofactor 2 precursor (HCII), and serum amyloid A-4 protein (SAA4), which exist in the urine specimen of a testee. The expression intensity of the biomarker can facilitate diagnosis of bladder cancer and evaluation of aggressiveness and malignancy of bladder cancer. Thereby, the physician can arrange an optimized treatment to achieve the best therapeutic effect.Type: ApplicationFiled: August 4, 2010Publication date: August 11, 2011Inventors: Yi-Ting Chen, Jau-Song Yu, Chien-Lun Chen, Yu-Sun Chang
-
Patent number: 7928064Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.Type: GrantFiled: November 14, 2005Date of Patent: April 19, 2011Assignee: GTC Biotherapeutics, Inc.Inventors: Paul DiTullio, Harry M. Meade, Edward S. Cole
-
Patent number: 7923217Abstract: Methods and reagents for determining antithrombin III (AT) in body fluids by adding an AT binding partner to the sample and determining the free AT binding partner.Type: GrantFiled: August 29, 2003Date of Patent: April 12, 2011Assignee: Roche Diagnostics Operations, Inc.Inventor: Adena Enno
-
Publication number: 20110053214Abstract: The present invention provides a novel lower eukaryotic host cell producing human-like glycoproteins characterized as having a terminal ?-galactose residue and essentially lacking fucose and sialic acid residues. The present invention also provides a method for catalyzing the transfer of a galactose residue from UDP-galactose onto an acceptor substrate in a recombinant lower eukaryotic host cell, which can be used as a therapeutic glycoprotein.Type: ApplicationFiled: July 21, 2010Publication date: March 3, 2011Applicant: GLYCOFI, INC.Inventors: Robert Collier Davidson, Tillman Ulf Gerngross, Stefan Wildt, Byung-Kwon Choi, Juergen Hermann Nett, Piotr Bobrowicz, Stephen Robin Hamilton
-
Publication number: 20100183589Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, and to methods of making these isolated blood proteins and to therapeutic compositions comprising them.Type: ApplicationFiled: March 31, 2010Publication date: July 22, 2010Applicant: VENTRIA BIOSCIENCEInventors: Ning Huang, Raymond L. Rodriguez, Frank E. Hagie, David M. Stalker
-
Publication number: 20100113754Abstract: The provision of an antithrombin composition having a desired ?-form content rate or ?-form content rate is required. The invention provides a process for producing an antithrombin composition having a desired ?-form content rate or ?-form content rate which is prepared by contacting an antithrombin-containing aqueous solution with a Cellufine Sulfate chromatography carrier.Type: ApplicationFiled: April 2, 2008Publication date: May 6, 2010Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Tsutomu Sugihara, Setsuko Onodera, Tomonari Urakubo, Toshiyuki Suzawa
-
Patent number: 7691810Abstract: The present invention provides a process for producing an antithrombin III composition comprising an antithrombin III molecule having complex type N-glycoside-linked sugar chains, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains.Type: GrantFiled: October 7, 2004Date of Patent: April 6, 2010Assignee: Kyowa Hakko Kirin Co., LtdInventors: Tsuyoshi Yamada, Mitsuo Satoh, Yutaka Kanda, Kazuya Yamano
-
Publication number: 20090258004Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, and to methods of making these isolated blood proteins and to therapeutic compositions comprising them.Type: ApplicationFiled: November 27, 2007Publication date: October 15, 2009Inventors: Ning Huang, Raymond L. Rodriquez, Frank E. Hagie, David M. Stalker
-
Patent number: 7332577Abstract: The invention discloses a purified albumin solution of human origin with low prekallicrein activator (PKA) activity and stability over time characterised in that it has an antithrombin content equal to or greater than 0.03 mg/g of albumin, and a process for production thereof by the partial extraction of the antithrombin during fractionation of the human plasma.Type: GrantFiled: July 19, 2005Date of Patent: February 19, 2008Assignee: Grifols, S.A.Inventors: Juan Ignacio Jorquera Nieto, Olga Santaeularia Lozano, Nuria Hosta Mateu
-
Patent number: 7001993Abstract: Human antithrombin variants showing a high protease inhibitory activity even in the absence of heparin wherein at least one of the amino acids at positions 78, 278, 378 and 380 in the amino acid sequence of natural human antithrombin is substituted by another amino acid. Preferable examples thereof are human antithrombin variants wherein the amino acid at position 78 is substituted by Phe; the amino acid at position 278 is substituted by Ala, Arg, Asn, Gly, His, Tyr or Val; the amino acid at position 378 is substituted by Lys, Asn or Val; and/or the amino acid at position 380 is substituted by Ala, Asp, Gly, His, lie, Leu, Asn, Pro, Arg, Thr, Tyr or Val.Type: GrantFiled: June 22, 2000Date of Patent: February 21, 2006Assignee: Aventis Pharma Ltd.Inventor: Takehiko Koide
-
Patent number: 6878813Abstract: The present invention discloses modified antithrombin III compounds and methods. The amino acid compounds of the present invention are useful in treating blood clotting disorders, as well as other disease states associated with enzymes in the coagulation pathway.Type: GrantFiled: December 11, 2001Date of Patent: April 12, 2005Assignees: Temple University - of the Commonwealth System of Higher Education, University of Utah Research FoundationInventors: Susan C. Bock, Veronique Picard, Pedram Zendehrouh
-
Patent number: 6777541Abstract: The present invention relates to a process for the preparation of a solution comprising a substantially pure isoform of AT-III, said process comprising separating the isoform AT-III&agr; from AT-III&bgr; on a calcium hydroxyphosphate-based adsorbent.Type: GrantFiled: January 19, 2001Date of Patent: August 17, 2004Assignee: Octapharma AGInventor: Göran Karlsson
-
Patent number: 6518406Abstract: The present invention relates to methods for purification of antithrombin-III (AT-III) by precipitation of impurities. The said methods comprise (a) adding, to a solution comprising antithrombin-III, a saccharide and citrate, in an amount sufficient for impurities to precipitate while antithrombin-III essentially remains in solution; (b) allowing impurities to precipitate; and (c) removing the precipitated impurities, thereby obtaining a solution comprising purified antithrombin-III. The invention also relates to pharmaceutical compositions, obtainable by the said methods, comprising purified antithrombin-III, as well as to reconstituted pharmaceutical compositions essentially free from visible particles.Type: GrantFiled: June 21, 2000Date of Patent: February 11, 2003Assignee: Octapharma AGInventor: Stefan Winge
-
Patent number: 6491965Abstract: Novel conjugates of glycosaminoglycans, particularly heparin and dermatan sulfate, and amine containing species and therapeutic uses thereof are described. In particular, mild methods of conjugating heparins to proteins, such as antithrombin III and heparin cofactor II, which provide covalent conjugates which retain maximal biological activity are described. Uses of these conjugates to prevent thrombogenesis, in particular in lung airways, such as found in infant and adult respiratory distress syndrome, and on surfaces in contact with blood are also described.Type: GrantFiled: December 17, 1996Date of Patent: December 10, 2002Assignee: Hamilton Civic Hospitals Research Development, Inc.Inventors: Leslie Berry, Maureen Andrew
-
Patent number: 6441145Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GaINAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.Type: GrantFiled: August 28, 1998Date of Patent: August 27, 2002Assignee: Genzyme Transgenics, Inc.Inventors: Paul DiTullio, Harry Meade, Edward S. Cole
-
Patent number: 6395880Abstract: A method of purifying antithrombin III (AT III) from a starting material containing an AT III/heparin complex or an AT III/heparinoid complex is disclosed. First, the method comprises adsorbing the AT III/heparin complex or the AT III/heparinoid complex on an anion exchanger material. Second, the method involves separating the AT III from the adsorbed AT III/heparin complex or an AT III/heparinoid complex by elution with a buffer having a pH ranging from 8.5 to 10.5 and a conductivity between 10 and 60 mS.Type: GrantFiled: May 26, 2000Date of Patent: May 28, 2002Assignee: Baxter AktiengesellschaftInventors: Yendra Linnau, Ernst Hetzl, H. Peter Matthiessen, Silvia Neppl, Wolfgang Schönhofer, Hans-Peter Schwarz
-
Patent number: 6395881Abstract: A process is disclosed for the baseline separation of the &agr; and &bgr; variants of antithrombin III AT-III. The process involves subjecting a sample comprising AT III to cyclodextrin-modified micellar electrokinetic chromatography (CD-MEKC). The CD-MEKC is performed with a buffer comprising boric acid, an anionic tensid, &bgr;-cyclodextrin, and an aliphatic diamine at a basic pH. The CD-MEKC results in the separation of the AT III into AT III &agr; and ATIII &bgr;. The anionic tensid can be sodium dodecyl sulfate and the aliphatic diamine can be 1, 5-diaminopentane.Type: GrantFiled: May 7, 2001Date of Patent: May 28, 2002Assignee: Aventis Behring GmbHInventors: Reiner Doenges, Juergen Roemisch, Harald Stauss
-
Patent number: 6093804Abstract: The methods of the present invention provide a simple means for separating active and inactive Alpha Proteinase Inhibitor (API). The methods further provide means for purifying API at high yield (>70%), and at levels of purity (>90%) and activity (>90%) not heretofore available. Moreover, the methods of the present invention are simple (i.e., two chromatographic steps) and efficient; and are thus especially suitable to large scale purification processes. These methods will contribute substantially to alleviating the unmet demand for API for therapeutic purposes.Type: GrantFiled: September 24, 1998Date of Patent: July 25, 2000Assignee: American National Red CrossInventors: Annemarie H. Ralston, William H. Drohan
-
Patent number: 5843705Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GaINAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.Type: GrantFiled: February 21, 1995Date of Patent: December 1, 1998Assignee: Genzyme Transgenic CorporationInventors: Paul DiTullio, Harry Meade, Edward S. Cole
-
Patent number: 5817765Abstract: Virus inactivating chemicals and/or detergents in an aqueous composition containing a water-soluble plasma protein are reduced by selecting a suitable combination of temperature and concentration above 0.5M of salt with a high salting out effect according to the Hofmeister series, thereby forming vesicles containing the virus inactivating chemical and/or detergent. These vesicles are removed from the aqueous phase, e.g. by phase separation or filtration, and the protein thereafter isolated from the aqueous phase. The water-soluble plasma protein can be e.g. antithrombin III, transferrin or albumin. When the aqueous phase comprises e.g. a salt of citrate or sulphate in a concentration above 1M at room temperature, the reduction of virus inactivating chemical or detergent can be as high as 2000 times or more, giving a final concentration below 5 ppm.Type: GrantFiled: October 30, 1995Date of Patent: October 6, 1998Assignee: Pharmacia & Upjohn AktiebolagInventors: Sven Isaksson, Stefan Winge
-
Patent number: 5767108Abstract: A method of treating a patient with a medical device having immobilized heparin on a blood-contacting surface in which the covalently attached heparinized surface is provided with an adsorbed protein which may be activated by the immobilized heparin to block the coagulation of fibrinogen. Antithrombin III is the preferred adsorbed protein. The adsorbed protein is maintained on the immobilized heparin surface until the medical device is placed into contact with the patient's blood. When in contact with the patient's blood, the adsorbed protein will prevent initial thrombin formation at the biomaterial-blood interface. The preadsorption of ATIII is accomplished under conditions advantageous to maximum heparin/ATIII binding. When the preadsorbed surface comes in contact with whole blood, the maximum advantage of prophlactic properties of ATIII/heparin are obtained.Type: GrantFiled: August 22, 1995Date of Patent: June 16, 1998Assignee: Medtronic, Inc.Inventors: Patrick Cahalan, Theo Lindhout, Benedict Fouache, Michel Verhoeven, Linda Cahalan, Marc Hendriks, Ron Blezer
-
Patent number: 5589516Abstract: A liquid preparation of antithrombin-III (AT-III), comprising an AT-III and an organic acid, a salt thereof, a sugar sulfate or a surfactant as a stabilizer, and a liquid preparation of AT-III, having a pH of 9-10. The preparation of the present invention is stable after long-term preservation and poses no clinical problems in terms of pharmacological effects and safety. The preparation is more advantageous than lyophilized preparations in that it does not require dissolution in injectable distilled water and can be used easily. Accordingly, the preparation is clinically very useful.Type: GrantFiled: December 5, 1994Date of Patent: December 31, 1996Assignee: The Green Cross CorporationInventors: Katsuhiro Uriyu, Akimasa Ohmizu, Hajime Fukuyama, Kazuo Takechi, Kazumasa Yokoyama
-
Patent number: 5439802Abstract: The present invention involves the determination of Protein S and Protein C activity in human plasma based on the addition of FIX.sub.a which indirectly influences the formation of thrombin.Type: GrantFiled: January 14, 1992Date of Patent: August 8, 1995Assignee: Chromogenix ABInventor: Steffen Rosen
-
Patent number: 5420252Abstract: A novel human antithrombin III (AT III) mutant having a high antithrombin activity in the absence of heparin and effective in the treatment of thrombotic disorders as an anticoagulant, which is obtained by mutating amino acids at the reactive site and the heparin binding site of human AT III into another amino acids with the use of the recombinant DNA technology with the use of a DNA coding for AT III as a template. The invention also relates to a method for mass producing the above-described mutant by incubating a host transformed by an expression vector having the cDNA of the mutant inserted therein.Type: GrantFiled: April 9, 1993Date of Patent: May 30, 1995Assignee: Eisai Co., Ltd.Inventors: Hiroyuki Kato, Shinji Yoshitake, Suguru Suzuki, Noboru Suzuki, Toshio Seto, Naoko Nagaoka, Yoshiharu Mizui
-
Patent number: 5385890Abstract: An antithrombin III is described comprising a lyophilized powder of antithrombin III and a polyoxyethylene glycol sorbitan alkyl ester as well as a kit composed of a container wherein a lyophilized powder of antithrombin III is placed and a solvent for the powder, characterized in that a polyoxyethylene glycol sorbitan alkyl ester is added to either or both of the powder and the solvent. The preparation has a high solubility in water by retaining its activity.Type: GrantFiled: September 30, 1993Date of Patent: January 31, 1995Assignee: Hoechst Japan LimitedInventors: Toshinobu Aoyama, Keizo Hirahara
-
Patent number: 5319072Abstract: A method for purifying human antithrombin III in an alcoholic solution at low temperature using bound heparin is provided.Type: GrantFiled: January 10, 1992Date of Patent: June 7, 1994Assignee: Alpha Therapeutic CorporationInventors: Yahiro Uemura, Swaraj Kaur, Prabir Bhattcharya
-
Patent number: 5252557Abstract: An antithrombin solution for preventing fibrin formations, including antithrombin at a concentration of more than 0.5 U/ml and not more than 250 U/ml, a physiological buffer and optionally sodium hyaluronate. A related surgical method includes applying the solution directly during surgery to exposed tissue. The solution can also be injected into the synovial cavity of patients with active arthritis as therapeutic orthopaedics.Type: GrantFiled: January 2, 1991Date of Patent: October 12, 1993Assignee: Kiyoshi KitaInventors: Kiyoshi Kita, Fumiaki Yoshitomi
-
Patent number: 5221614Abstract: A method for determination of biological activity of AT III which comprises mixing a specimen, AT III free-extrinsic coagulation factor-containing plasma, heparin and a prothrombin time-measuring reagent or a factor X-activating reagent and then measuring a coagulation time, and a reagent and plasma to be used therefor.Type: GrantFiled: October 25, 1991Date of Patent: June 22, 1993Assignee: Nippon Shoji Kabushiki KaishaInventor: Masayasu Enomoto
-
Patent number: 5151266Abstract: Methods are disclosed for increasing the solubility of antibodies and their radioisotope, toxin, or drug immunoconjugates and for reducing the non-specific uptake of antibody, either conjugated or unconjugated, into the RES organs such as via Fc receptor-mediated mechanisms. The methods involve incubation of the reactive component with amphipathic molecules, such as an anionic detergent, to achieve the desired result. A preferred anionic detergent in this regard is sodium dodecylsulfate.Type: GrantFiled: December 22, 1988Date of Patent: September 29, 1992Assignee: NeoRx CorporationInventors: A. Charles Morgan, Jr., Gowsala Pavanasasivam
-
Patent number: 5138034Abstract: A method of fractionating plasma protein which comprises treating a plasma protein-containing material in the following sequence of steps, provided that steps (ii) through (v) may be performed in an optional order: (i) freeze-thaw treatment, (ii) treatment at 5 to 10% ethanol concentration, (iii) treatment with an anion exchanger, (iv) affinity chromatography with immobilized lysine, (v) affinity chromatography with immobilized heparin, (vi) treatment at 18 to 30% ethanol concentration, (vii) treatment at 35 to 45% ethanol concentration.Type: GrantFiled: June 14, 1990Date of Patent: August 11, 1992Assignee: The Green Cross CorporationInventors: Yahiro Uemura, Kazuo Takechi, Kenji Tanaka
-
Patent number: 5093237Abstract: A method for determination of biological activity of AT III by measuring coagulating time of blood plasma comprises mixing a specimen having AT III free-extrinsic coagulation factor-containing plasma, heparin and a prothrombin time-measuring reagent or a factor X-activating reagent and then measuring the coagulation time, and a reagent and plasma to be used therefor.Type: GrantFiled: November 2, 1989Date of Patent: March 3, 1992Assignee: Nippon Shoji Kabushiki KaishaInventor: Masayasu Enomoto
-
Patent number: 5091177Abstract: The present invention is concerned with novel monoclonal antibodies which define a glycolipid antigen associated with human non-small cell lung carcinomas ("NSCLC") and certain other human carcinomas. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antibodies find use in diagnostic methods such as the detection of malignant cells associated with NSCLC and in therapeutic methods. The invention also comprises a method for determining the presence of a malignant condition in lung tissue and other human tissue. The method involves examining the human tissue for the presence of a glycolipid antigen having the characteristics of a ganglio-N-triosylceramide.Type: GrantFiled: May 11, 1990Date of Patent: February 25, 1992Assignee: OncogenInventors: Ingegerd Hellstrom, Joseph P. Brown, Karl E. Hellstrom, Diane Horn, Peter Linsley
-
Patent number: 5084273Abstract: An anticoagulant containing as active ingredients protein C or activated protein C and heparin has a high anticoagulant activity which cannot be obtained with activated protein C or heparin alone. The activity of the anticoagulant is further increased by addition of AT III.Type: GrantFiled: December 21, 1990Date of Patent: January 28, 1992Assignee: Hoechst Japan LimitedInventor: Keizo Hirahara
-
Patent number: 5053492Abstract: Monoclonal antibodies to Mojave toxin and use for isolation of cross-reacting proteins in Crotalus venoms are disclosed. Hybridomas secreting monoclonal antibodies against Mojave toxin were established. The antibodies were used for identifying cross-reacting proteins in individual C. s. scutulatus and other Crotalus venoms and to isolate Mojave toxin. The antibodies recognized five bands with a pI range from 5.1 to 6.1 in immunoblots of electrofocused crude venom and Mojave toxin purified by immunoaffinity chromatography. The specificity of the antibodies was for the basic subunit of the toxin which resolved into four bands of pI between 9.3 and 9.6. Individual C. s. scutulatus venoms of snakes from Texas and southern Arizona had multiple bands with pI's ranging from 4.9 to 6.3. Cross-reacting proteins were also recognized by antibodies in the electrophoresed venoms of C. basiliscus, C. d. durissus, C. d. terrificus, C. h. horridus, and C. v.Type: GrantFiled: August 7, 1986Date of Patent: October 1, 1991Assignee: Board of Regents, The University of Texas SystemInventors: Eppie D. Rael, Richard J. Salo
-
Patent number: 4945054Abstract: The present invention relates to a process for separating and purifying proteases and antiproteases. This process is characterized in that there are placed in contact an insoluble cross-linked polymer including in its chain the group --SO.sub.3 R.sub.1 -- and/or the group --SO.sub.2 R.sub.2 -- in which R.sub.1 denotes a hydrogen atom or metal and R.sub.2 denotes the remainder of an amino acid linked to the --SO.sub.2 -- bridge through its amine --NH--, function, with the solution containing proteases and antiproteases or their complex; separating the polymer which has absorbed the desired protein, washing it carefully with the buffer, desorbing the absorbed protein by a solution of a polycationic compound in the case of T or by an albumin solution in the case of AT or of the complex T-AT, and isolating the protein, if desired, by known means, such as, especially, freeze drying. The invention is useful for studying the mechanism of blood coagulation.Type: GrantFiled: May 17, 1983Date of Patent: July 31, 1990Assignee: Commissariat a l'Energie AtomiqueInventors: Christine Fougnot, Marcel Jozefowicz, Robert D. Rosenberg
-
Patent number: 4900720Abstract: To maintain an almost unchanged plasma-protein profile in a patient subsequent to plasma exchange, the plasma-exchange medium contains the most essential human serum proteins, except for the coagulation factors, at a concentration of 75 g/l.Type: GrantFiled: April 6, 1987Date of Patent: February 13, 1990Assignee: Boitest Pharma GmbHInventor: Ronald Kotitschke
-
Patent number: 4883784Abstract: The administration of Factor I and/or Factor H to a mammal has been found to alleviate or prevent such autoimmune diseases as systemic lupus erythematosus, rheumatoid arthritis and glomerulonephritis.Type: GrantFiled: April 13, 1988Date of Patent: November 28, 1989Assignee: Sankyo Company LimitedInventor: Isao Kaneko
-
Patent number: 4749783Abstract: Preparation of active therapeutic proteins comprising two essential steps. In the first step an active protein source is treated under conditions sufficient to inactivate any viruses present (e.g. via heat or chemical treatment). In the second step, the treated active protein source of moderate purity is then treated under conditions sufficient to remove impurities as well as denatured (once active) proteins resulting from the viral inactivation step. In an illustrative embodiment, a biologically active protein such as antithrombin is treated under conditions sufficient to assure viral inactivation and minimal antithrombin deactivation. After the viral inactivation, the antithrombin is contacted with immobilized heparin to complex only the active antithrombin which is then eluted by known means and processed further (e.g., to include desired excipients and then freeze dried).Type: GrantFiled: July 11, 1986Date of Patent: June 7, 1988Assignee: Miles Laboratories, Inc.Inventors: Robert E. Jordan, Jaleh Kilpatrick